Healthcare Industry News: HSMN NewsFeed
News Release - May 18, 2017
Biotheranostics Appoints Don Hardison as New CEODiagnostics Industry Leader Steps Up from Board of Directors to Bolster Reimbursement Position, Expand Clinical Utility of Diagnostic Tools
SAN DIEGO, May 18, 2017 -- (Healthcare Sales & Marketing Network) -- Biotheranostics, Inc., a growing molecular diagnostics company, today announced the appointment of Don Hardison as Chief Executive Officer. Hardison, who was elected to the Board of Directors in July 2016, transitioned into the CEO role earlier this year. Hardison succeeds Nicolas Barthelemy, who led the Company's spin-out from its former corporate parent, positioning it as an independent growth company. In his role as CEO, Hardison will lead the company as it continues its commercial growth and focuses on key activities to expand clinical applications of and access to its proprietary cancer diagnostics products, CancerTYPE IDŽ (CTID) and Breast Cancer IndexSM (BCI).
Hardison brings more than 30 years of diagnostics experience to Biotheranostics and will leverage his proven track record of commercial and operational success in complex healthcare reimbursement environments. From 2000-2007, he was CEO of EXACT Sciences, and also held senior leadership roles at Laboratory Corporation of America, Quest Diagnostics, and SmithKline Beecham. Most recently, Hardison was President, CEO, and Director of Good Start Genetics, Inc.
"I am honored to be a part of a company that provides such meaningful, personalized diagnostic information to improve cancer treatment and am especially grateful to Nicolas for his leadership as it provided a solid foundation for us to move forward," said Hardison. "In this challenging reimbursement environment, my primary goal will be to strengthen our reimbursement position so that the patients that need them most have access to our tests." He continued, "I plan to focus our organization on continued commercial growth and on development activities that expand the clinical utility of both of our products and am excited to be leading the company through the next phase of its growth."
About Breast Cancer Index
BCI is a molecular, gene expression-based test uniquely positioned to help identify patients best suited for extended endocrine treatment. It is the only validated, commercially available test with data demonstrating prognostic risk of recurrence out to 15 years, as well as prediction of likelihood of benefit from extended endocrine therapy (treatment in years 5-10). The breakthrough test helps oncologists and patients navigate the difficult trade-off between the benefit of preventing disease recurrence and the risk of significant side effects and safety challenges related to extended endocrine therapy. For more information, visit www.breastcancerindex.com.
BCI was recently endorsed by the European Group for Tumor Markers (EGTM) to predict outcome and aid in adjuvant therapy decision-making for ER+ positive early-stage breast cancer patients. In the endorsement, the EGTM specifically highlighted the ability of BCI to detect risk of late recurrences (>5 years post-diagnosis) and cited research demonstrating that BCI showed improved performance versus several other biomarkers in predicting late recurrence. According to the guidelines, "BCI may thus be of value for the identification of ER-positive lymph node-negative patients that may not require extended endocrine therapy after 5 years of treatment."
About CancerTYPEŽ ID
CancerTYPE ID is the market-leading molecular, gene expression-based test focused on the classification of metastatic cancer and is intended to aid in the diagnosis of the tumor type and subtype of cancers with diagnostic uncertainty, in conjunction with standard clinical and pathological assessment. Commercially launched in 2010, CancerTYPE ID is a standardized, objective molecular test based on the differential expression of 92 genes that classifies tumors by matching the gene expression pattern of a tumor specimen to a database of known tumor types and histological subtypes. CancerTYPE ID is able to classify 50 cancer types and subtypes, representing more than 95 percent of all solid tumors based on incidence.
Biotheranostics, Inc., is a leader in helping physicians improve the care of cancer patients, offering proprietary genomics-based molecular diagnostics that allow treatment to be tailored to individual patients. The company's Breast Cancer Index and CancerTYPE ID tests address a variety of unmet medical needs in the management of cancer patients, and extensive clinical studies have confirmed the accuracy, clinical validity, clinical utility, and cost-effectiveness of the tests. Biotheranostics operates a CLIA-certified, CAP-accredited diagnostic laboratory in San Diego. Learn more at biotheranostics.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.